Accessibility Menu
Halozyme Therapeutics Stock Quote

Halozyme Therapeutics (NASDAQ: HALO)

$65.89
(-1.5%)
-0.99
Price as of October 22, 2025, 1:25 p.m. ET

KEY DATA POINTS

Current Price
$65.89
Daily Change
(-1.5%) $0.99
Day's Range
$65.87 - $67.36
Previous Close
$66.88
Open
$67.03
Beta
0.85
Volume
355,822
Average Volume
2,052,388
Market Cap
7.8B
Market Cap / Employee
$66.88M
52wk Range
$42.01 - $79.5
Revenue
-
Gross Margin
0.78%
Dividend Yield
N/A
EPS
$4.38
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Halozyme Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
HALO+29.19%+115.12%+16.56%+1,512%
S&P+15.06%+95.03%+14.29%+501%

Halozyme Therapeutics Company Info

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

News & Analysis

The Fool has written over 100 articles on Halozyme Therapeutics.

Financial Health

General

Q2 2025YOY Change
Revenue$325.72M40.8%
Gross Profit$261.60M50.4%
Gross Margin80.31%5.1%
Market Cap$6.41B-3.8%
Market Cap / Employee$18.31M0.0%
Employees350-6.2%
Net Income$165.16M77.1%
EBITDA$222.90M62.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$61.86M-67.1%
Accounts Receivable$316.34M47.5%
Inventory181.513.9%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.51B0.4%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets27.70%9.9%
Return On Invested Capital35.96%7.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$98.15M84.4%
Operating Free Cash Flow$99.71M78.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings18.9413.9316.9311.88-41.46%
Price to Book16.0813.4321.6013.29-64.53%
Price to Sales7.866.077.455.48-29.27%
Price to Tangible Book Value-18.97-15.85-17.28-20.11109.61%
Price to Free Cash Flow TTM18.9713.1716.3011.95-27.91%
Enterprise Value to EBITDA45.1436.2854.5833.29-40.82%
Free Cash Flow Yield5.3%7.6%6.1%8.4%38.72%
Return on Equity111.8%198.4%147.1%179.1%16.97%
Total Debt$1.50B$1.54B$1.51B$1.51B0.44%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.